Nedlands

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma5 trials
• Lung cancer2 trials
• Alzheimer disease1 trial
• Asthma1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial

Phase

• Phase 35 trials
• Phase 1/22 trials
• Phase 22 trials
• Phase 11 trial

Status

• Active, not recruiting4 trials
• Completed4 trials
• Recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• GlaxoSmithKline10 trials

Running trials

• Recruiting

  Open-label Extension Study in Participants With Early Alzheimer's Disease

  NCT07105709· Phase 2· GlaxoSmithKline· Source

  Contact: Daniel Clarke (principal investigator)

• Active, not recruiting

  First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

  NCT05277051· Phase 1· GlaxoSmithKline· Source

• Active, not recruiting

  Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

  NCT04484623· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT04246047· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04162210· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting

Closed trials

• Recruiting

  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  NCT07099898· Phase 3· GlaxoSmithKline· Source

• Recruiting

  A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  NCT05714839· Phase 1/2· GlaxoSmithKline· Source

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source

• Completed

  To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT03544281· Phase 1/2· GlaxoSmithKline· Source